Alan Pollack, MD
Internal Medicine · Rockville, MDNPI 1790781979
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,170 of the $3,025 with a category attached, or 71.7%. 26 manufacturers reported payments, led by Pfizer at 46.9% of the total. Reporting peaked in 2019 at $2,141 and has fallen 93.7% since, to $135 in 2024.
Across 109 payments — averaging $27.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$1K
- AbbVie$243
- AstraZeneca$204
- Novo Nordisk$187
- Merck$174
- Amgen$135
- plus $664 from 20 others
Across 159 payments — averaging $13,235 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$1.2M
- Bavarian Nordic A/s$933K
What the payments were for
- Consulting fees$120%
- Travel & lodging$84428%
- Food & beverage$2,17072%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 17 | $1,419 |
| AbbVie(2 entities) | 12 | $243 |
| AstraZeneca | 12 | $204 |
| Novo Nordisk | 11 | $187 |
| Merck | 15 | $174 |
| Amgen | 7 | $135 |
| GSK | 5 | $88 |
| Mylan Specialty L.p. | 3 | $64 |
| Johnson & Johnson(2 entities) | 2 | $50 |
| Lilly USA, LLC | 3 | $49 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $46 |
| Regeneron Healthcare Solutions, Inc. | 2 | $40 |
| Abbott | 2 | $38 |
| Sanofi Pasteur Inc. | 2 | $38 |
| Intercept Pharmaceuticals, Inc. | 2 | $29 |
| Teva Pharmaceuticals USA, Inc. | 1 | $28 |
| Mallinckrodt Enterprises LLC | 1 | $23 |
| Bausch & Lomb Americas Inc. | 1 | $23 |
| Lifescan, Inc. | 1 | $23 |
| Radius Health, Inc. | 1 | $22 |
| E.r. Squibb & Sons, L.L.C. | 1 | $22 |
| Phathom Pharmaceuticals, Inc. | 1 | $20 |
| Biohaven Pharmaceuticals, Inc. | 1 | $19 |
| Gilead | 1 | $17 |
| Corcept Therapeutics | 1 | $16 |
| Dynavax Technologies Corporation | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PREVNAR - 13$1,240
How this compares
$3,025 in reported general payments places this provider in the 85th percentile of 2,979 internal medicine providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 48 | $72,916 |
| EliquisApixaban | 31 | $46,285 |
| OzempicSemaglutide | 17 | $33,731 |
| Breo ElliptaFluticasone/Vilanterol | 42 | $32,546 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 15 | $25,377 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 17 | $20,929 |
| SymbicortBudesonide/Formoterol Fumarate | 37 | $16,065 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 41 | $7,335 |
| Pulmicort FlexhalerBudesonide | 14 | $5,094 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 34 | $5,012 |
| Wixela InhubFluticasone Propion/Salmeterol | 22 | $4,287 |
| BreynaBudesonide/Formoterol Fumarate | 12 | $4,195 |
| Testosterone | 11 | $3,485 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 106 | $3,284 |
| Atorvastatin Calcium | 241 | $2,970 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $88 | $126,391107 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Pulmicort Flexhaler | $204 | $46,53666 claims |
| PfizerEliquis | $1,419 | $46,28531 claims |
| Novo NordiskOzempic | $187 | $33,73117 claims |
| AbbVieSynthroid | $243 | $1,63532 claims |
| Teva Pharmaceuticals USA, Inc.Albuterol Sulfate | $28 | $48513 claims |
| Lilly USA, LLCOlanzapine | $49 | $48411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,979 internal medicine providers in Maryland.
Other internal medicine in Rockville
- Scott KoenigRockville$20K
- Marianne MannHighland$2.1M
- Param DedhiaBaltimore$636K
- Curtis RosebraughAshton$418K
- Mark CorriereColumbia$402K
- Gregory PokrywkaTowson$377K
- Shawn DhillonBaltimore$227K
- Brian HarveyAnnapolis$220K
- Jeremy SugarmanBaltimore$210K
- Florence HounPotomac$161K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.